Bio Essence

Bio Essence Long-term Debt

The Long-Term Debt of Bio Essence (BIOE) as of Oct 23, 2026 is 56,156.00 USD. In the previous year, Long-Term Debt was 55,124.00 USD — a change of 1.87% (higher).

Long-term Debt

56,156.00USD

YoY

1.87%

Last updated:

Long-Term Debt of Bio Essence is 2025 56,156.00 USD. Long-Term Debt of Bio Essence was 2024 55,124.00 USD. It decreases by 1.87% higher compared to the previous year.

The Bio Essence Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2020
212,750.00 USD
Jan 1, 2021
249,091.00 USD
Jan 1, 2022
235,867.00 USD
Jan 1, 2023
199,607.00 USD
Jan 1, 2024
55,124.00 USD
Jan 1, 2025
56,156.00 USD
The Bio Essence Long-term Debt history
YEARLong-term DebtYoY
56,156.00USD+1.87%
55,124.00USD-72.38%
199,607.00USD-15.37%
235,867.00USD-5.31%
249,091.00USD+17.08%
212,750.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Essence Stock analysis

What does Bio Essence do? Bio Essence Corp. generates revenue through its three subsidiaries: Bio Essence Pharmaceutical (BEP), which operates as a health supplement original equipment manufacturer (OEM) service provider; Bio Essence Herbal Essentials (BEH), which targets healthcare practitioners with herbal products including granules, capsules, pills, and tablets, and offers special formulation services; and McBE Pharma (McBE), which develops, manufactures, and sells prescription drugs. The company's products are sold directly to healthcare practitioners such as dietitians and nutraceutical practitioners, who then recommend them to their patients. BEH specifically serves practitioners in the integrative healthcare market, providing both standard and custom-formulated herbal supplements. BEP functions as an OEM for health supplement manufacturers, producing private-label products under other brands. McBE Pharma focuses on prescription drugs, targeting healthcare providers for direct sales. The firm's direct connections with practitioners enable it to reach end consumers through professional recommendations rather than retail channels. Bio Essence Herbal Essentials Inc. (BEH) emphasizes its role in connecting practitioners with patients through tailored herbal supplement solutions. The company's revenue streams are derived from the sale of herbal health supplements, vitamin nutritional supplements, and prescription drugs. BEH's target segment includes practitioners who specialize in integrative healthcare, such as dietitians and nutraceutical practitioners, who use the company's products to support patient care. McBE Pharma's segment consists of healthcare providers seeking prescription drug solutions for their patients. BEP serves as a manufacturing partner for other supplement brands, supplying OEM services. Bio Essence is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Essence stock

Long-Term Debt of Bio Essence is 56,156.00 USD in 2025.

Long-Term Debt of Bio Essence changed from 55,124.00 USD to 56,156.00 USD, representing a 1.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Bio Essence since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Bio Essence historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bio Essence

All Key Metrics — Bio Essence